Specifically, he developed latanoprost sold under the trade name Xalatan, which is the most widely used glaucoma medication.
[1] As a molecular biophysics and biochemistry major at Yale University, Dr. Camras first conceived the idea that low doses of prostaglandins could be effective in lowering intraocular pressure in glaucoma.
In medical school at Columbia University, Dr. Camras sought out a research adviser who would work with him on his project.
After many rejections, he partnered with a renowned researcher-novelist Dr. László Z. Bitó who agreed to work with him on the project.
[1] Together with the help of Johan Stjernschantz at Pharmacia, the three developed the prostaglandin analogue, latanoprost, which remains the leading treatment in glaucoma therapy.